Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5'UTR variants in three-generational pedigree

J. Trizuljak, P. Likavcová, K. Staňo Kozubík, Z. Vrzalová, J. Hynšt, T. Deissová, J. Štika, L. Radová, M. Prudková, J. Vaculová, I. Blaháková, P. Smejkal, J. Kamelander, Š. Pospíšilová, M. Doubek

. 2024 ; 35 (1) : 2388103. [pub] 20240830

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018625

Inherited thrombocytopenias (ITs) encompass a group of rare disorders characterized by diminished platelet count. Recent advancements have unveiled various forms of IT, with inherited thrombocytopenia 2 (THC2) emerging as a prevalent subtype associated with germline variants in the critical 5' untranslated region of the ANKRD26 gene. This region is crucial in regulating the gene expression of ANKRD26, particularly in megakaryocytes. THC2 is an autosomal dominant disorder presenting as mild-to-moderate thrombocytopenia with minimal symptoms, with an increased risk of myeloproliferative malignancies. In our study of a family with suspected IT, three affected individuals harbored the c.-118C>T ANKRD26 variant, while four healthy members carried the c.-140C>G ANKRD26 variant. We performed a functional analysis by studying platelet-specific ANKRD26 gene expression levels using quantitative real-time polymerase-chain reaction. Functional analysis of the c.-118C>T variant showed a significant increase in ANKRD26 expression in affected individuals, supporting its pathogenicity. On the contrary, carriers of the c.-140C>G variant exhibited normal platelet counts and no significant elevation in the ANKRD26 expression, indicating the likely benign nature of this variant. Our findings provide evidence confirming the pathogenicity of the c.-118C>T ANKRD26 variant in THC2 and suggest the likely benign nature of the c.-140C>G variant.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018625
003      
CZ-PrNML
005      
20241024111255.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/09537104.2024.2388103 $2 doi
035    __
$a (PubMed)39212265
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trizuljak, Jakub $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
245    10
$a Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5'UTR variants in three-generational pedigree / $c J. Trizuljak, P. Likavcová, K. Staňo Kozubík, Z. Vrzalová, J. Hynšt, T. Deissová, J. Štika, L. Radová, M. Prudková, J. Vaculová, I. Blaháková, P. Smejkal, J. Kamelander, Š. Pospíšilová, M. Doubek
520    9_
$a Inherited thrombocytopenias (ITs) encompass a group of rare disorders characterized by diminished platelet count. Recent advancements have unveiled various forms of IT, with inherited thrombocytopenia 2 (THC2) emerging as a prevalent subtype associated with germline variants in the critical 5' untranslated region of the ANKRD26 gene. This region is crucial in regulating the gene expression of ANKRD26, particularly in megakaryocytes. THC2 is an autosomal dominant disorder presenting as mild-to-moderate thrombocytopenia with minimal symptoms, with an increased risk of myeloproliferative malignancies. In our study of a family with suspected IT, three affected individuals harbored the c.-118C>T ANKRD26 variant, while four healthy members carried the c.-140C>G ANKRD26 variant. We performed a functional analysis by studying platelet-specific ANKRD26 gene expression levels using quantitative real-time polymerase-chain reaction. Functional analysis of the c.-118C>T variant showed a significant increase in ANKRD26 expression in affected individuals, supporting its pathogenicity. On the contrary, carriers of the c.-140C>G variant exhibited normal platelet counts and no significant elevation in the ANKRD26 expression, indicating the likely benign nature of this variant. Our findings provide evidence confirming the pathogenicity of the c.-118C>T ANKRD26 variant in THC2 and suggest the likely benign nature of the c.-140C>G variant.
650    _2
$a lidé $7 D006801
650    12
$a trombocytopenie $x genetika $7 D013921
650    12
$a 5' nepřekládaná oblast $7 D020121
650    12
$a rodokmen $7 D010375
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a mezibuněčné signální peptidy a proteiny $7 D036341
655    _2
$a časopisecké články $7 D016428
700    1_
$a Likavcová, Paulína $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Staňo Kozubík, Kateřina $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Vrzalová, Zuzana $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Hynšt, Jakub $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Deissová, Tereza $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Štika, Jiří $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Radová, Lenka $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Prudková, Marie $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Department of Clinical Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republicand
700    1_
$a Vaculová, Jana $u Department of Clinical Haematology and Haematooncology, Hospital Havířov, Havířov, Czech Republic
700    1_
$a Blaháková, Ivona $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Smejkal, Petr $u Department of Clinical Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republicand
700    1_
$a Kamelander, Jan $u Department of Clinical Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republicand
700    1_
$a Pospíšilová, Šárka $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Doubek, Michael $u Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic $u Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000212696282
773    0_
$w MED00005009 $t Platelets $x 1369-1635 $g Roč. 35, č. 1 (2024), s. 2388103
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39212265 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111249 $b ABA008
999    __
$a ok $b bmc $g 2201496 $s 1230598
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 35 $c 1 $d 2388103 $e 20240830 $i 1369-1635 $m Platelets $n Platelets $x MED00005009
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace